September 28, 2020
During Blood Cancer Awareness Month, Know AML spoke to Gail Roboz, a world-leading doctor in AML. We asked, "Have there been any clinical trials targeting the NPM1 gene specifically?" In this video, Gail describes the importance of NPM1 mutations and how this effects the type of treatment given. She mentions the role of menin inhibitors in early clinical trials for NPM1 mutated AML.